Fri 12/23/2022 09:43 AM
BVI Medical’s recovery stalled in the third quarter as adverse currency movements and changes to reimbursement rates in Korea impacted the topline of the global manufacturer of eye surgery products. However, the group managed to continue deleveraging, with net debt to EBITDA improving to 6.93x by the end of the quarter, sources said.
Sales fell 5.3% year over year to $71.3 million in the third quarter of 2022. The drop was mainly due to the rise in the U.S. dollar versus the euro exchange...
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.